

**TOWNSEND and TOWNSEND and CREW LLP**

Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
(415) 576-0200

In re application of: Patrick Coleman et al

Application No.: 09/515,014

Filed: February 29, 2000

Group Art Unit:

For: SYNTHETIC ANTIGEN FOR THE DETECTION OF  
ANTIBODIES IMMUNOREACTIVE WITH HIV VIRUS**THE ASSISTANT COMMISSIONER FOR PATENTS**  
Washington, D.C. 20231AmendmentAttorney Docket No. 09197-008810USDate: May 02, 2000I hereby certify that this is being deposited with the United States  
Postal Service as first class mail in an envelope addressed to:Assistant Commissioner for Patents  
Washington, D.C. 20231Signed: Kim M. Goplen

Sir:

Transmitted herewith is an amendment in the above-identified application.

- ☐ Enclosed is a petition to extend time to respond.  
☐ Small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.  
☐ A verified statement to establish small entity status under 37 CFR 1.9 and 1.27 is enclosed.  
☒ Information Disclosure Statement

If any extension of time is needed, then this response should be considered a petition therefor.  
The filing fee has been calculated as shown below:

(Col. 1)	(Col. 2)	(Col. 3)		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA
TOTAL	* 24	MINUS	** 25	= 0
INDEP.	* 4	MINUS	*** 4	= 0
<input type="checkbox"/> FIRST PRESENTATION OF MULTIPLE DEP. CLAIM				

## SMALL ENTITY

RATE	ADDIT. FEE
x \$9.00 =	
x \$39.00 =	
+ \$130.00 =	
TOTAL ADDIT. FEE	

OTHER THAN  
SMALL ENTITY

RATE	ADDIT. FEE
x \$18.00 =	\$0.00
x \$78.00 =	\$0.00
+ \$260.00 =	
OR TOTAL	\$0.00

- \* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.  
\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.  
\*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, then write "3" in this space. The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

☒ No fee is due.

Please charge Deposit Account No. 20-1430 as follows:

- ☐ Claims fee \$ \_\_\_\_\_  
☒ Any additional fees associated with this paper or during the pendency of this application.

NO extra copies of this sheet are enclosed.

TOWNSEND and TOWNSEND and CREW LLP

Brian W. PoorBrian W. Poor, Reg. No.: 32,928  
Attorneys for Applicants

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:


Assistant Commissioner for Patents, Washington, D.C. 20231

On 5-2-00

TOWNSEND and TOWNSEND and CREW LLP

By: Kim M. Gopler

PATENT  
Attorney Docket No.: 09197-008810US



P#2

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Patrick Coleman et al.

Application No.: 09/515,014

Filed: February 29, 2000

For: SYNTHETIC ANTIGEN FOR THE  
DETECTION OF ANTIBODIES  
IMMUNOREACTIVE WITH HIV  
VIRUS

Examiner: Not Assigned

Art Unit: Not Assigned

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR §1.97 and  
§1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

AA U.S. Patent No. 4,629,783 issued 12/16/86 to Cosand.

AB U.S. Patent No. 5,206,136 issued 04/27/93 to Monji et al.

AC U.S. Patent No. 5,439,792 issued 08/08/95 to Blake et al.

AD WO 83/02277

AE EP 0 267 802

AF Berent et al., "Comparison of Oligonucleotide and Long DNA Fragments as Probes in DNA and RNA Dot, Southern, Northern, Colony and Plaque Hybridizations," Biotechniques 3(3):208-219 (1985).

AG Clavel et al., "Isolation of a New Human Retrovirus from West African Patients with AIDS," Science 233(4761):343-346 (1986).

AH De Leys et al., "Isolation and Partial Characterization of an Unusual Human Immunodeficiency Retrovirus from Two Persons of West-Central African Origin," J. Virol 64(3):1207-1216 (1990).

AI Gürtler et al., "A New Subtype of Human Immunodeficiency Virus Type 1 (MVP-5180) from Cameroon," J. Virol. 68(3):1581-1585 (1994).

AJ Guyader et al., "Genome organization and transactivation of the human immunodeficiency virus type 2," Nature 326:662-669 (1987).

AK Ratner et al., "Complete nucleotide sequence of the AIDS virus, HTLV-III," Nature 313:277-284 (1985).

AL Tam et al., "SN2 Deprotection of Synthetic Peptides with a Low Concentration of HF in Dimethyl Sulfide: Evidence and Application in Peptide Synthesis," Am. Chem. Soc. 105:6442-6455 (1983).

Applicants believe that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No.

20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Dated: 2 May 2000

Brian W. Poor  
Brian W. Poor  
Reg. No. 32,928

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: 206-467-9600  
Fax: 206-623-6793  
BWP:kmg

SE 5003152 v1